Featured Content: To Display at Bottom of Article

Findings from the SAVE study showed that an all-oral revumenib-based combination may improve responses in patients with acute myeloid leukemia with certain genetic alterations.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Smoking may contribute to genetic mutations and disease progression in myelodysplastic syndromes, a recent study found.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Bicistronic CD19/CD22 CAR T-cell therapy had improved safety, durability, and high remission rates in pediatric patients with R/R B-ALL.

John Marshall, MD, discussed zolbetuximab, which the FDA recently approved for patients with CLDN18.2–positive locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.